ArticleInternational journal of pharmaceutics: X2026
Hyaluronic acid microneedle patch for transdermal delivery of naringin-loaded PEGylated terpesomes in a rat model of rheumatoid arthritis: Modulation TGF-β1, oxidative stress, and inflammation.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Polymer Microneedles for Localized Drug Delivery in Musculoskeletal Tissue Regeneration.Journal of functional biomaterials · 2026Review
- Advanced azelaic acid hyalubilosome-loaded microneedles for potent anti-inflammatory, antioxidant, and antimicrobial for Acne treatment by up-regulation of Nrf2/HO-1 signaling pathway.International journal of pharmaceutics: X · 2026Article
- Innovative HPMC/PVP K90 Dissolving Microneedles Incorporating Tacrolimus-Loaded Cubosomes: A Novel Strategy for Managing Allergic Conjunctivitis.Pharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that causes progressive joint damage and systemic effects. Naringin (NRG), a citrus-derived flavonoid with potent anti-inflammatory and antioxidant activities, is hindered by poor solubility and low bioavailability in clinical applications. NRG was encapsulated into PEGylated terpesomes (TPs) prepared by thin-film hydration using phosphatidylcholine, terpenes, and sodium deoxycholate, then integrated into hyaluronic acid-based microneedles (NRG-TPs/HA-MNs) to create a dual-mechanism transdermal delivery system. Optimized NRG-loaded terpesomes possessed a nanoscale particle size (218 ± 0.67 nm), a narrow polydispersity index (PDI: 0.32 ± 0.05), a high entrapment efficiency (79 ± 0.23%), and strong colloidal stability (Zeta potential: -36.37 ± 0.87). HA-MN patches exhibited remarkable mechanical strength, high drug loading (>93%), and successful skin penetration. NRG release was sustained for over 48 h, and transdermal permeation was significantly improved compared to free NRG in both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.